The CFO Economics
of Accountable Access

CHAPTER 01 / 10

Executive thesis

My investment thesis is that accountable care creates enterprise value only when clinical improvement survives four tests: the organization can deliver the intervention, demonstrate the incremental effect, retain an agreed share of the benefit and convert that benefit into cash after delivery and capital costs. Failure at any one stage can leave a clinically useful program with a weak investment return. The CFO’s role is to price those dependencies before committing resources.

I would evaluate access, care management and risk-bearing contracts as a portfolio of contingent obligations. Define the population, the intervention, the counterfactual and the party receiving each cash flow. Then test how enrollment, utilization, attribution, settlement and working capital interact. The 2026–2030 horizon in this essay is a planning frame; it is not a forecast that policy alignment or data infrastructure will make returns predictable.

Four imperatives for CFOs

01 / Revenue quality matters

Sustainable value comes from risk-adjusted, recurring revenue with measurable outcomes, not top-line growth alone.

02 / Medical cost is a portfolio

Costs vary by population, condition, and intervention. Treat medical cost as a portfolio to actively manage risk, mix and trend.

03 / Cash is not earnings

Accounting profit differs from cash generation. Convert medical savings into real cash through disciplined settlement, working capital, and reinvestment choices.

04 / Capital efficiency determines value

The ability to generate an attractive, risk-adjusted return on required capital ultimately drives enterprise value.

Source cited in the original: Framework informed by CMS, New York State DOH, NAIC, public company filings, and peer-reviewed literature (2025–2026).

CHAPTER 02 / 10

Executive summary & market inflection

The policy developments discussed here create several possible routes to longer-term payment accountability. They do not establish a uniform transition for every New York provider or a guaranteed reduction in medical spending. I would separate the contracts the organization can enter, the obligations each creates and the investment required to perform under them. A model with a longer horizon may support sustained care investment while also increasing exposure to medical trend, attribution changes and execution risk.

The strategic choice is therefore selective participation. Compare each opportunity with the existing business, including the cost of capabilities that cannot be recovered if the contract underperforms. Favor commitments whose clinical and financial mechanisms can be tested before the largest fixed investment is made. Policy ambition identifies where to investigate; the organization’s own economics determines where to commit.

Five structural shifts changing accountable-care economics

01 / Accountability is deepening in MSSP and Medicare accountable care.

Higher performance standards, greater downside risk, and more sophisticated benchmarking are accelerating the shift from upside-only models to true two-sided risk requiring more disciplined care management and financial execution.

02 / LEAD creates a long-duration 2027–2036 benchmark and risk horizon.

The CMS LEAD model establishes a 10-year performance window, providing unprecedented stability for planning, capital deployment, and population health investment.

03 / ACCESS creates an outcome-paid chronic-care supply layer.

The ACCESS model builds a dedicated, outcome-based infrastructure for chronic care, expanding the supply of services and enabling earlier intervention, better health outcomes, and lower total cost of care.

04 / AHEAD and hospital global budgets reprice hospital incentives.

New York’s AHEAD model and global budgets align hospital economics with population health, reducing incentives for avoidable utilization and creating stronger incentives for care coordination and community health investment.

05 / Interoperability and New York social-care infrastructure reduce data and access friction.

CMS-0057-F API requirements and New York’s social-care infrastructure (NYHER, HIE, community networks) improve data liquidity, close care gaps, and enable more coordinated, equitable access to services across the enterprise and community.

The strategic question is no longer how large the network can become, but who can orchestrate access while preserving longitudinal accountability and retained enterprise value.

Source cited in the original: CMS, New York State DOH, public filings, and peer-reviewed literature (2025–2026).

CHAPTER 03 / 10

Revenue quality, risk adjustment & Medicare Advantage yield

Decomposing MA revenue yield is essential to capital allocation and long-term value creation.

Executive summary

Medicare Advantage revenue yield is shaped by more than the annual CMS rate announcement. For 2027, CMS finalized an average expected payment increase of approximately 2.48% before coding trend. 2026 completed the transition to the 2024 CMS-HCC risk adjustment model, creating a more stable baseline for future years. Going forward, yield will reflect a combination of base rate growth, risk-model normalization, changes in diagnosis sources, quality performance, and other policy and mix factors. For health-plan CFOs, decomposing these components is critical to separate true earnings power from temporary or non-recurring effects.

Key points

• CMS finalized an average expected payment increase of approximately 2.48% for 2027 before coding trend.
• 2026 completed the transition to the 2024 CMS-HCC risk adjustment model, creating a more stable baseline.
• Revenue yield reflects multiple components beyond the base rate, including risk model changes, diagnosis sources, quality performance, and organizational mix.

MLR boundary condition

Medicare Advantage plans must maintain a minimum Medical Loss Ratio (MLR) of 85% (benefits plus quality improvement expenses). This means that lower medical cost does not translate one-for-one into margin, as a significant portion of any savings must be reinvested in member benefits or quality improvement activities. CFOs must evaluate revenue yield and medical cost performance together, recognizing the MLR constraint when assessing earnings power.

Risk adjustment is a revenue-accuracy function, rather than a coding-growth exercise. Its purpose is to ensure payments reflect member health status, not to drive unlimited revenue growth.

Revenue growth must be decomposed into price, risk, quality, mix, policy, and membership before it is treated as true earnings power.

Source cited in the original: CMS Final Rate Announcement (CY 2027), CMS-HCC Model Information, Medicare Advantage Regulations, industry analysis, public company filings, and peer-reviewed literature (2025–2026).

CHAPTER 04 / 10

Medical cost as a portfolio & the CFO value bridge

Understanding the flow from risk-adjusted revenue to economic profit — and where CFOs can create value through disciplined medical cost management, investment, and capital allocation.

Disciplined medical cost management translates care performance into economic value.

Source-table note. The original labels total incurred medical cost at $7.0B. Its listed categories sum to 103% and $7.21B. The figures are reproduced as published; they do not form a reconciled allocation. The bridge also uses the combined label “Economic profit / free cash flow”; the article distinguishes these measures below.

Intervention ROI formula

Key insight

Cash receipts, accounting margin, shared savings, and free cash flow are distinct — and each tells a different story.

CFOs should reconcile medical savings, accounting profit, cash flow, and economic profit in one model before committing capital to care or growth.

Source cited in the original: Framework informed by CMS, New York State DOH, NAIC, public company filings, and peer-reviewed literature (2025–2026).

CHAPTER 05 / 10

LEAD 2027–2036: long-duration benchmark economics

From Prospective Payment to Enterprise Value. A 10-Year Model for Sustainable, Accountable Growth.

The source article presents LEAD as a long-horizon opportunity for accountable-care investment. I would evaluate that horizon as the duration of both a potential benefit and a potential obligation. A longer planning period can support prevention and delivery redesign, but it does not by itself make cash flow predictable. The investment case still depends on the actual benchmark terms, attribution, quality obligations, risk exposure and the capital required to withstand adverse experience.

Key model elements

• 10-year model horizon: begins in 2027, spanning 2027–2036.
• Quality withhold: 3%, held for quality performance.
• Benchmark discount / hurdle: aligned with CMS methodology and market dynamics.
• Administrative add-on: 1.5%, for eligible higher-spending ACOs.
• Capitation & advanced payments: primary care capitation; total care capitation; non-primary care capitation; advanced payment options.
• Risk mitigation: risk corridors; stop-loss protection; financial guarantees.

Short-term settlements → Long-duration enterprise asset.

CFO interpretation

Prospective payment changes liquidity, not necessarily margin.

The real question for CFOs is the incremental expected return versus the incremental tail risk and required capital. LEAD should be evaluated as a portfolio decision — balancing cash flow stability, risk exposure, and strategic optionality over the full 10-year horizon.

Source cited in the original: Framework informed by CMS, New York State DOH, NAIC, public company filings, and peer-reviewed literature (2025–2026).

CHAPTER 06 / 10

ACCESS: outcome-priced chronic care as an underwriting problem

A Financial Framework to Turn Care Delivery Into Measurable, Investable Value.

I approach outcome-aligned chronic-care payment as an underwriting problem: what service is being purchased, what evidence establishes performance, what it costs to deliver and what remains collectible after the contract is applied. The ACCESS discussion in the original article motivates that framework. It does not establish that every intervention becomes a predictable portfolio asset or that clinical improvement will produce retained medical savings within a buyer’s budget period.

PCP co-management economics are roughly $30 per qualifying coordination service, up to three times annually; plus a one-time onboarding payment where applicable.

The ACCESS learning window

2026–2027 / Portfolio-learning period

• Deploy interventions
• Collect real-world evidence
• Measure clinical and financial outcomes
• Refine targeting, operations, and unit economics

2028 onward / Enter ACO economics

• ACCESS expenditures begin entering relevant ACO economics
• Apply validated outcomes to contracting, pricing, and capital allocation
• Scale high-performing interventions
• Drive sustained medical cost reduction and enterprise value

Intervention underwriting

An intervention is financially attractive when the risk-adjusted, persistent medical cost savings exceed the intervention cost.

ACCESS turns chronic-care capacity into a priceable external intervention class; the finance question is return on the healthcare dollar, not technology novelty.

Source cited in the original: Framework informed by CMS, New York State DOH, NAIC, public company filings, and peer-reviewed literature (2025–2026).

CHAPTER 07 / 10

AHEAD, hospital global budgets & social-care infrastructure

Aligning Hospital Payment Reform with Community Care to Drive a Healthier, More Resilient New York.

AHEAD & hospital economics

New York’s AHEAD model moves hospital economics from volume-based, fee-for-service toward prospective global budgets, with stronger integration with advanced primary care. This shift rewards better outcomes, population health, and total cost management — not higher volumes.

Today: activity-based hospital economics

• Fee-for-service payments
• Incentive to increase volume
• Fragmented care across settings
• Higher cost, variable outcomes

Align → Invest → Integrate → Measure → Improve

AHEAD: global budgets & advanced primary care

• Prospective global budgets
• Incentive for value and population health
• Stronger hospital–primary care integration
• Coordinated care across medical and social services
• Lower cost, better outcomes, more equitable care

A transformation of more than $5B

New York’s AHEAD-related transformation has been described as more than $5B in payment transformation across participating hospitals and payers.

Evidence from Maryland’s experience

• $1.6B — approximate Medicare savings from 2014–2022 under Maryland’s global budget model.
• 11 percentage points — lower hospital utilization than other states over 2013–2023, mainly through outpatient changes.

Incentive alignment across hospital and non-hospital care matters. Global budgets work best when paired with strong primary care, behavioral health, and social care investments.

NYHER & Social Care Networks

The NYHER waiver creates a statewide framework to invest in social-care infrastructure, connecting health plans, providers, and community organizations. With $7.5B in total waiver funding — including up to $500M for Social Care Networks through March 2027 — New York can build a more integrated, community-based system that addresses health-related social needs (HRSN) and improves both health outcomes and total cost of care.

NYHER social care operating model

• $7.5B — NYHER waiver package to strengthen health and social care infrastructure.
• Up to $500M — for Social Care Networks through March 2027.

People & Communities: Healthier Lives / Stronger Neighborhoods / Greater Equity.

CFO insight

Social care must be evaluated as medical-cost ROI and persistence, not as a parallel mission program.

Source cited in the original: CMS AHEAD Model; Maryland Total Cost of Care Model evaluations; NYHER 1115 waiver materials; public filings and peer-reviewed literature.

CHAPTER 08 / 10

Data liquidity, prior authorization & the financial value of reduced latency

Interoperability as Operating Infrastructure.

Executive perspective

I would finance interoperability according to the decision it can improve and the work required to act on it. Moving a claim, clinical event or authorization record sooner can reduce delay, but only if identity, meaning, timeliness and responsibility survive the exchange. An earlier signal has little operating value when nobody can resolve the exception or the receiving service lacks capacity. The business case must include that response capability as well as the data connection.

Interoperability layer / Decision engine

Normalize → Analyze → Apply rules → Generate insight → Drive action.

CMS-0057-F: APIs for a more connected healthcare system

The CMS-0057-F Interoperability and Prior Authorization rule advances national standards for data exchange through three key APIs:

• Provider Access API — Member data access for authorized providers.
• Payer-to-Payer API — Data exchange when members change plans.
• Prior Authorization API — Electronic prior authorization exchange.

Key requirements broadly begin in 2027, with phased implementation and expanded data sets to follow.

The financial value of less distance

Reducing the distance between signal and action creates measurable financial value.

Signal: Claim; Clinical Event; Risk Alert; Prior Auth Request; Network Change.

Shorter Distance / Lower Cost / Higher Value.

Action: Intervene; Authorize; Coordinate; Allocate Capital; Improve Outcomes.

• Fewer avoidable acute events
• Lower administrative expense
• Higher provider productivity
• Better member experience
• Stronger medical margin

Data liquidity turns speed into savings — and savings into a healthier tomorrow.

Source cited in the original: CMS-0057-F, CMS Interoperability and Prior Authorization Rule (2024), industry literature, and author analysis (2025–2026).

CHAPTER 09 / 10

Capital allocation, ROIC & tail-risk scenarios

Disciplined capital for durable value in a lower-cost, higher-quality New York | 2026–2030.

Own / Partner / Enable / Exit

• Own — Build and scale core capabilities that create durable advantage.
• Partner — Share risk and scale through strategic relationships.
• Enable — Provide capital, data and capabilities to accelerate ecosystem value.
• Exit — Divest or sunset non-core assets to redeploy capital.

Risk-adjusted return on healthcare capital

Risk-adjusted return on healthcare capital (RARHC) measures the after-tax economic value generated per dollar of capital at risk, including both required capital (e.g., regulatory, risk, and working capital) and incremental operating capital (e.g., growth investments).

Note: Illustrative scenarios for planning purposes. Percentages reflect directional sensitivity versus base case.

Initiative portfolio: return vs. capital intensity

The original portfolio illustration compares expected return and relative capital intensity across Behavioral Health, Chronic-Care Programs, Primary Care (Integrated), Home-Based Care, Social Care, Data Infrastructure, and Risk Protection.

Behavioral Health is shown with the highest expected return, followed by Primary Care (Integrated), Chronic-Care Programs, Home-Based Care, Social Care, Data Infrastructure, and Risk Protection. Social Care appears at the lowest relative capital intensity; Risk Protection at the highest.

The portfolio graphic provides relative positions without exact point values or a bubble-size legend. This text describes its ordering without assigning numerical returns.

Key takeaway

The base case is not the strategy; the distribution of outcomes is the strategy.

I would use the portfolio illustration to identify hypotheses for diligence, not to rank investments as if the plotted returns had been estimated. Each proposed commitment needs its own expected cash flows, downside exposure, capital requirement and clinical objective. Diversification helps only when the underlying risks are sufficiently different; several programs dependent on the same payer, workforce or attribution mechanism can fail together.

Source cited in the original: Framework informed by CMS, New York State DOH, NAIC, public company filings, and peer-reviewed literature (2025–2026).

CHAPTER 10 / 10

Public-market lens, board scorecard & final executive lesson

Closing the loop from market signals to board oversight to enduring enterprise value.

01 / What public markets actually watch

Investors track a consistent set of indicators across leading health plans. Recent examples illustrate the signals that matter most — medical-cost trend, reserve development, cash conversion, leverage, and quality-driven revenue.

02 / Board-level scorecard

Boards should connect medical-cost trend, reserve development, cash conversion, leverage, and quality-driven revenue to the investment decisions under review.

03 / Executive lesson

In accountable care, capability is the scarce asset.

Durable healthcare enterprise value depends on the ability to price risk, underwrite interventions, coordinate access, convert lower medical cost into cash, and retain an attractive risk-adjusted return on required capital. The board’s task is to test that chain: which investments improve care, which savings the enterprise can retain, when those savings become cash, and whether the return compensates for the capital at risk.

Source cited in the original: CMS, New York State DOH, NAIC, public company filings, and peer-reviewed literature (2025–2026).